{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:10:02Z","timestamp":1776013802476,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Drug Investigation"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s40261-012-0044-y","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T18:06:46Z","timestamp":1355940406000},"page":"93-94","source":"Crossref","is-referenced-by-count":5,"title":["Fidaxomicin in the Treatment of Clostridium difficile-Associated Diarrhoea"],"prefix":"10.1007","volume":"33","author":[{"given":"James","family":"Greig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"44_CR1","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1007\/BF03261906","volume":"32","author":"DA Sclar","year":"2012","unstructured":"Sclar DA, Robison LM, Oganov AM, Schmidt JM, Bowen KA, Castillo LV. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin Drug Investig. 2012;32:e17\u201324.","journal-title":"Clin Drug Investig"},{"key":"44_CR2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New Engl J Med. 2011;364:422\u201331.","journal-title":"New Engl J Med"},{"key":"44_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281\u20139.","journal-title":"Lancet Infect Dis"},{"key":"44_CR4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"SH Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431\u201355.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"44_CR5","unstructured":"Dificlir, UK prescribing information. UK: Astellas; 2012."},{"key":"44_CR6","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","volume":"55","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55:S154\u201361.","journal-title":"Clin Infect Dis"},{"key":"44_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","volume":"81","author":"PN Wiegand","year":"2012","unstructured":"Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81:1\u201314.","journal-title":"J Hosp Infect"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0044-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0044-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:49Z","timestamp":1559489329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0044-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0044-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,12]]}}}